• Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Psychedelic Invest

Investing in Psychedelics

  • Home
  • News
    • Analysis
    • Interviews
    • Press
  • Index
  • Resources
    • Psychedelic Investors
    • Psychedelic Stocks
    • Psychedelic Law Firms
    • Events
    • Jobs
  • Invest

Novamind Expands Psychedelic Medicine Access in Utah

Quick Take:

  • Novamind Inc. announced the expansion and optimization of its Cedar Psychiatry clinic in Layton, Utah.
  • This is the largest clinic in the company’s network.

Novamind Inc. (NM) (“Novamind” or the “Company”), a mental health company specialized in psychedelic medicine, announces the expansion and optimization of its Cedar Psychiatry clinic in Layton, Utah (“Layton Clinic”), the largest clinic in the Company’s network.

The redesigned Layton Clinic now offers improved treatment rooms to accommodate a higher number of ketamine and Spravato™ (esketamine) treatments. The Layton Clinic expansion comes in response to a significant increase in demand for ketamine therapies across Novamind’s mental health clinics. In 2020 alone, the Cedar Psychiatry clinic network facilitated over 20,000 client visits, an increase of over 100 percent compared to the same period in 2019.

The demand for mental health services continues to increase dramatically and we are responding by improving access to our most innovative treatments. The enhanced clinic layout enables us to serve more clients with evidence-based treatments, including ketamine and future FDA approved psychedelics.”

Dr. Reid Robison – Chief Medical Officer and Director of Novamind

Cedar Psychiatry has gained years of experience in effectively managing the challenges associated with offering its clients access to novel medications such as Spravato™ and anticipated FDA-approved psychedelics. Cedar Psychiatry’s expertise includes inventory logistics, coordinating reimbursement with insurance providers and compliance with each medications’ unique Risk Evaluation and Mitigation Strategy (REMS).

“Enhancing service offerings at our Layton clinic goes to the heart of our mission, which is to increase our clients’ access to alternative mental health treatments,” said Yaron Conforti, CEO and Director of Novamind. “In 2021, Novamind will address the increasing demand for innovative mental health services by growing our network of Cedar Psychiatry clinics within Utah and into new jurisdictions.”

As a leading provider of ketamine therapy in the United States, Cedar Psychiatry has administered over 4,000 ketamine sessions and over 1,700 Spravato™ treatments since its founding in 2016. The Cedar Psychiatry clinic network has four locations in Utah, in Salt Lake City, Layton, Orem and Springville. For more information on the clinics, please visit our website.

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

  • Facebook
  • LinkedIn
  • RSS
  • Twitter

The Next Wave
of BioTech

Subscribe to our newsletter to get the latest business and investing news about the burgeoning psychedelics industry.

Recent Posts

  • Mydecine Innovations Group Files Application to list to the NASDAQ January 27, 2021
  • Field Trip Health Ltd. Announces Opening of Field Trip Health Center in Atlanta, GA, as it Continues Expansion in the US January 26, 2021
  • Champignon Brands’ Canadian Rapid Treatment Center of Excellence Opens First Community-Based Centre in Ottawa to Provide Ketamine Treatment for Adults With Depression January 25, 2021
  • PharmaTher Signs License Agreement for Patented Ketamine Treatment January 22, 2021
  • January, 2021 Update: Psychedelic Index Adds 7 New Companies January 22, 2021
Psychedelics by TradingView

Interview Series

journey colab psychedelics
fluence psychedelic therapy
CaaMTech Davis Wuolle

Footer

Psychedelic Investor

Psychedelics are set to disrupt the multi billion dollar alcohol, tobacco, pharmaceutical, and health & wellness industries.

There is an enormous opportunity for those early investors who are able to look past the historical negative stigma associated with many psychedelics.

Psychedelic Invest is a resource for those looking to invest in the psychedelic industry.

Quick Links

  • About
  • Contact
  • Terms of Use
  • Psychedelic Stock Index
  • Careers

Subscribe

Copyright © 2021 · Psychedelic Invest